Osel Inc.

Osel Inc. is a biotechnology company founded in 1996 with a vision to develop and commercialize Live Biotherapeutic Products (LBPs) addressing abnormal conditions resulting from disruptions in the human microbiome. The company, a pioneer in this field, received FDA authorization in 2003 to test a live bacterial therapeutic, demonstrating its significant regulatory progress and experience. Osel's proprietary approach involves identifying differences between healthy and disease-related microbiomes and leveraging beneficial microbes to treat dysbioses. The company's primary focus is on women’s health, targeting recurrent urinary tract infections and bacterial vaginosis, with a secondary focus on gastrointestinal tract disorders. Ongoing clinical trials and a product pipeline with two clinical stage products highlight Osel’s exciting therapeutic potential, positioning the company as an innovative player in the biotechnology and healthcare sectors. With its headquarters in the United States, Osel Inc. presents a promising investment opportunity in the growing field of Live Biotherapeutic Products.